Prognostic effect of serum C-reactive protein kinetics on advanced renal cell carcinoma treated with sunitinib

Fujita,Tetsuo; Tabata,Ken‑Ichi; Ishii,Daisuke; Matsumoto,Kazumasa; Yoshida,Kazunari; Iwamura,Masatsugu

doi:10.3892/mco.2017.1201

Prognostic effect of serum C-reactive protein kinetics on advanced renal cell carcinoma treated with sunitinib

Authors:
- Tetsuo Fujita
- Ken‑Ichi Tabata
- Daisuke Ishii
- Kazumasa Matsumoto
- Kazunari Yoshida
- Masatsugu Iwamura
View Affiliations

Affiliations: Department of Urology, Kitasato University School of Medicine, Sagamihara, Kanagawa 252‑0374, Japan
Published online on: March 20, 2017 https://doi.org/10.3892/mco.2017.1201
Pages: 691-696

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

C-reactive protein (CRP) is an independent prognostic factor for renal cell carcinoma (RCC). The aim of the present study was to investigate the prognostic effect of pretreatment serum CRP level and CRP kinetics on patients with advanced RCC treated with sunitinib. A total of 56 consecutive patients with advanced RCC treated with sunitinib between December, 2008 and December, 2012 were enrolled in the present study. The patients were retrospectively divided into 3 cohorts according to pretreatment serum CRP level and CRP kinetics: i) Normal CRP cohort (pretreatment CRP ≤0.30 mg/dl); ii) normalized CRP cohort (pretreatment CRP >0.30 mg/dl that normalized within 2 cycles of treatment); and iii) non-normalized CRP cohort (pretreatment CRP >0.30 mg/dl that did not normalize after sunitinib initiation). Disease control rate, progression‑free survival and overall survival times were compared for the 3 cohorts. The normal (n=17, 30.4%) and the normalized (n=8, 14.3%) CRP cohorts exhibited significantly better disease control rates compared with the non‑normalized CRP cohort (n=31, 55.4%; P<0.0001 and P=0.0445, respectively). The normal CRP cohort exhibited significantly longer progression‑free survival compared with the non‑normalized CRP cohort (P=0.0050). The normal and normalized CRP cohorts exhibited significantly longer overall survival compared with the non‑normalized CRP cohort (P=0.0005 and 0.0466, respectively). Therefore, CRP kinetics and normal pretreatment CRP level are prognostic indicators in patients with advanced RCC treated with sunitinib.

View Figures

View References

1	Tillett WS and Francis T: Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med. 52:561–571. 1930. View Article : Google Scholar : PubMed/NCBI
2	Grivennikov SI, Greten FR and Karin M: Immunity, inflammation, and cancer. Cell. 140:883–899. 2010. View Article : Google Scholar : PubMed/NCBI
3	Koo AS, Armstrong C, Bochner B, Shimabukuro T, Tso CL, deKernion JB and Belldegrum A: Interleukin-6 and renal cell cancer: Production, regulation, and growth effects. Cancer Immunol Immunother. 35:97–105. 1992. View Article : Google Scholar : PubMed/NCBI
4	Oya M, Takayanagi A, Horiguchi A, Mizuno R, Ohtsubo M, Marumo K, Shimizu N and Murai M: Increased nuclear factor-kappa B activation is related to the tumor development of renal cell carcinoma. Carcinogenesis. 24:377–384. 2003. View Article : Google Scholar : PubMed/NCBI
5	Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani JM, Moskovtchenko JF, et al: Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 52:3317–3322. 1992.PubMed/NCBI
6	Saito K and Kihara K: Role of C-reactive protein in urological cancers: A useful biomarker for predicting outcomes. Int J Urol. 20:161–171. 2013. View Article : Google Scholar : PubMed/NCBI
7	Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 356:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
8	Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, et al: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 27:3584–3590. 2009. View Article : Google Scholar : PubMed/NCBI
9	Fujita T, Iwamura M, Ishii D, Tabata K, Matsumoto K, Yoshida K and Baba S: C-reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib. Int J Urol. 19:908–913. 2012. View Article : Google Scholar : PubMed/NCBI
10	Yasuda Y, Saito K, Yuasa T, Kitsukawa S, Urakami S, Yamamoto S, Yonese J, Takahashi S and Fukui I: Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Int J Clin Oncol. 18:884–889. 2013. View Article : Google Scholar : PubMed/NCBI
11	Beuselinck B, Vano YA, Oudard S, Wolter P, De Smet R, Depoorter L, Teghom C, Karadimou A, Zucman-Rossi J, Debruyne PR, et al: Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib. BJU Int. 114:81–89. 2014. View Article : Google Scholar : PubMed/NCBI
12	Teishima J, Kobatake K, Hayashi T, Seno Y, Ikeda K, Nagamatsu H, Hieda K, Shoji K, Miyamoto K, Inoue S, et al: Prognostic significance of C-reactive protein in patients with intermediate-risk metastatic renal cell carcinoma treated with molecular targeted therapy. Oncol Lett. 8:881–885. 2014.PubMed/NCBI
13	Fujikawa K, Matsui Y, Oka H, Fukuzawa S and Takeuchi H: Serum C-reactive protein level and the impact of cytoreductive surgery in patients with metastatic renal cell carcinoma. J Urol. 162:1934–1937. 1999. View Article : Google Scholar : PubMed/NCBI
14	Tatokoro M, Saito K, Iimura Y, Fujii Y, Kawakami S and Kihara K: Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. J Urol. 180:515–519. 2008. View Article : Google Scholar : PubMed/NCBI
15	Saito K, Tatokoro M, Fujii Y, Iimura Y, Koga F, Kawakami S and Kihara K: Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma. Eur Urol. 55:1145–1154. 2009. View Article : Google Scholar : PubMed/NCBI
16	Ito K, Yoshii H, Sato A, Kuroda K, Asakuma J, Horiguchi A, Sumitomo M and Asano T: Impact of postoperative C-reactive protein level on recurrence and prognosis in patients with N0M0 clear cell renal cell carcinoma. J Urol. 186:430–435. 2011. View Article : Google Scholar : PubMed/NCBI
17	Shinohara N, Kumagai A, Kanagawa K, Maruyama S, Abe T, Sazawa A and Nonomura K: Multicenter phase II trial of combination therapy with meloxicam, a cox-2 inhibitor, and natural interferon-alpha for metastatic renal cell carcinoma. Jpn J Clin Oncol. 39:720–726. 2009. View Article : Google Scholar : PubMed/NCBI
18	Lamb GW, McMillan DC, Ramsey S and Aitchison M: The relationship between the preoperative systemic inflammatory response and cancer-specific survival in patients undergoing potentially curative resection for renal clear cell cancer. Br J Cancer. 94:781–784. 2006. View Article : Google Scholar : PubMed/NCBI
19	Ito K, Asano T, Yoshii H, Satoh A, Sumitomo M and Hayakawa M: Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma. Int J Urol. 13:1365–1370. 2006. View Article : Google Scholar : PubMed/NCBI
20	Komai Y, Saito K, Sakai K and Morimoto S: Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU Int. 99:77–80. 2007. View Article : Google Scholar : PubMed/NCBI
21	Karakiewicz PI, Hutterer GC, Trinh QD, Jeldres C, Perrotte P, Gallina A, Tostain J and Patard JJ: C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: A European study of 313 patients. Cancer. 110:1241–1247. 2007. View Article : Google Scholar : PubMed/NCBI
22	Atzpodien J, Royston P, Wandert T and Reitz M: DGCIN-German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group: Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer. 88:348–353. 2003. View Article : Google Scholar : PubMed/NCBI
23	Casamassima A, Picciariello M, Quaranta M, Berardino R, Ranieri C, Paradiso A, Lorusso V and Guida M: C-reactive protein: A biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J Urol. 173:52–55. 2005. View Article : Google Scholar : PubMed/NCBI
24	Gauldie J, Richards C, Harnish D, Lansdorp P and Baumann H: Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA. 84:7251–7255. 1987. View Article : Google Scholar : PubMed/NCBI
25	Miki S, Iwano M, Miki Y, Yamamoto M, Tang B, Yokokawa K, Sonoda T, Hirano T and Kishimoto T: Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett. 250:607–610. 1989. View Article : Google Scholar : PubMed/NCBI